DelMar Pharmaceuticals Announces Completion Of $10.5 Million Oversubscribed Offering
03/09/2013

Charles Vista, LLC. Gregg Lorenzo
, acted as the company's placement agent in the unit offering. Each unit consists of one share of
common stock and one common stock purchase warrant.

Online PR News – 09-March-2013 – New York – DelMar Pharmaceuticals Announces Completion Of $10.5 Million Oversubscribed Offering And Appointment Of I nvestor Relations Consultant

Booke & Co. to Provide I nvestor Relations Counsel

DelMar Pharmaceuticals, Inc.
(OTCQB: DMPI) ("DelMar") today announced the completion of a $10.5 million private placement.

Charles Vista, LLC. Gregg Lorenzo
, acted as the company's placement agent in the unit offering. Each unit consists of one share of
common stock and one common stock purchase warrant. The maximum offering in the Private Placement consisted of
9,375,000 units for gross proceeds of $7.5 million. In addition, the placement agent has been granted an over-
allotment option. The overallotment option was increased to 3,750,000 Units for additional gross proceeds of $3.0
million to accommodate investor interest. The overallotment option has been exercised in full in conjunction with this
closing.

"We are very pleased with the strong interest in our private placement. These funds will position us to accelerate the
advancement of our ongoing VAL-083 clinical trials for refractory glioblastoma, the most common and aggressive form
of brain cancer," stated DelMar Pharma President & CEO Jeffrey Bacha.

The Company also announced that it has retained Booke and Co., New York City, to be its investor relations counsel.

Mr. Bacha stated, "We are very excited to announce the engagement of Booke and Company. We are very impressed
with their years of experience and successful results in advising companies in all industries. Their strong creditability
and wealth of contacts within the investment community will complement our ongoing relationship with LifeSci
Advisors, LLC and leverage our success as a public company. We look to a long and productive relationship."

About VAL-083

VAL-083 represents a 'first in class' small-molecule chemotherapeutic. VAL-083 has been assessed in multiple NCI -
sponsored clinical studies in various cancers including lung, brain, cervical, ovarian tumors and leukemia. Published
pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types. VAL-083 is approved
as a cancer chemotherapeutic in China for the treatment of chronic myelogenous leukemia and lung cancer
.

Based on published research, the mechanism of action of VAL-083 is understood to be a bi-functional alkylating agent;
however, the functional groups associated with alkylating events has been shown to differ from other alkylating agents
used in the treatment of GBM.

VAL-083 has previously demonstrated activity in cyclophosphamide, BCNU and phenylanine mustard resistant cell lines
and no evidence of cross-resistance has been encountered in published clinical studies. Based on the presumed
alkylating functionality of VAL-083, published literature suggests that DNA repair mechanisms associated with Temodar
and nitrosourea resistance, such as 06-methylguanine methyltransferace (MGMT), may not confer resistance to VAL-
083.

VAL-083 readily crosses the blood brain barrier where it maintains a long half-life in comparison to the plasma.
Published preclinical and clinical research demonstrates that VAL-083 is selective for brain tumor tissue.

VAL-083 has been assessed in multiple studies as chemotherapy in the treatment of newly diagnosed and recurrent
brain tumors. In general, tumor regression was achieved following therapy in greater than 40% of patients treated
and stabilization was achieved in an additional 20% - 30%. In published clinical studies, VAL-083 has previously been
shown to have a statistically significant impact on median survival in high grade gliomas when combined with radiation
vs. radiation alone.

The main dose-limiting toxicity related to the administration of VAL-083 in previous clinical studies was
myelosuppression. No significant hepatic, renal or pulmonary toxicity has been reported in the literature or overseas
commercial experience.

About Glioblastoma Multiforme (GBM)

Glioblastoma multiforme (GBM) is the most common and most malignant form of brain cancer. Of the estimated
17,000 primary brain tumors diagnosed in the United States each year, approximately 60% are gliomas. Attention was
drawn to this form of brain cancer when Senator Ted Kennedy was diagnosed with glioblastoma and ultimately died
from it.

Newly diagnosed patients suffering from GBM are initially treated through invasive brain surgery, although disease
progression following surgical resection is nearly 100%. Temozolomide (TemodarTM) in combination with radiation is
the front-line therapy for GBM following surgery. TemodarTM currently generates more than US$950 million annually in
global revenues primarily from the treatment of brain cancer.

Approximately 60% of GBM patients treated with Temodar® experience tumor progression within one year.
Bevacizumab (Avastin® ) has been approved for the treatment of GBM in patients failing Temodar® . According to the
Avastin® label, approximately 20% of patients failing TemodarTM respond to AvastinTM therapy. Analysts anticipate
annual Avastin® revenues for the treatment of brain cancer may reach US$650 million by 2016.

Approximately 48% of patients who are diagnosed with GBM will fail both front-line therapy and AvastinTM. DelMar
Pharma estimates that the market for treating GBM patients the post-Avastin failure exceeds US$200 million annually
in North America.

About the VAL-083 Clinical Study

The Phase I/ II study is an open-label, single arm dose-escalation study designed to evaluate the safety, tolerability,
pharmacokinetics and anti-tumor activity of VAL-083 in patients with histologically confirmed initial diagnosis of primary
WHO Grade IV malignant glioma (GBM), now recurrent. Patients with prior low-grade glioma or anaplastic glioma are
eligible, if histologic assessment demonstrates transformation to GBM. Patients with secondary brain tumors due to
CNS metastases are also eligible for the study.

GBM patients must have been previously treated for GBM with surgery and/ or radiation, if appropriate, and must have
failed both Bevacizumab (Avastin® ) and temozolomide (Temodar® ), unless either or both are contra-indicated.

Response to therapy and disease progression will be evaluated by MRI prior to each treatment cycle. An initial phase
of the study will involve dose escalation cohorts until a maximum tolerated dose (MTD) is established in the context of
modern care. Once the modernized dosing regimen has been established, additional patients will be enrolled at the
MTD (or other selected optimum dosing regimen).

DelMar Pharma is conducting the study under the direction of Dr. Howard Burris at the Sarah Cannon Research
Institute in Nashville, Tennessee with a second center in Sarasota, Florida. In November 2012, DelMar presented
interim data from the clinical trial at the Society for NeuroOncology Annual Meeting demonstrating that VAL-083 is well
tolerated and that some patients having failed prior therapy showed stable disease or tumor regression at doses tested
to date. DelMar is continuing to evaluate VAL-083 to determine an optimal dose for Phase II and registration studies
of VAL-083 in patients with GBM.

Please refer to clinicaltrials.gov identifier NCT01478178 for further details on this clinical trial.

About DelMar Pharma

DelMar Pharmaceuticals was founded in 2010 to develop and commercialize proven cancer therapies in new orphan
drug indications where patients are failing modern targeted or biologic treatments. The Company's lead asset, VAL-
083, is currently undergoing clinical trials in the United States as a potential treatment for refractory glioblastoma
multiforme (GBM), the most common and aggressive form of brain cancer. VAL-083 benefits from extensive clinical
research sponsored by the US National Cancer Institute, and is currently approved for the treatment of chronic
myelogenous leukemia (CML) and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083
may be active against a range of tumor types via a novel mechanism of action.

About Booke and Company, Inc.

Booke and Company, Inc., a leading independent financial investor relations consulting firm, develops and maintains
investor interest for public company clients. Through the years, it has developed a disciplined, dedicated approach to
building long-term shareholder value in a professional and well- managed investor relations process. The company's
comprehensive financial investor relations programs focuses on maximizing visibility within the investment community
for client companies that cover the range from large-cap, mid-cap, small-cap to micro-cap companies in both the
domestic and international arenas.

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking
statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking
statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties.
The factors that could cause actual future results to differ materially from current expectations include, but are not
limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its
technology; the expected benefits and efficacy of the Company's products and technology; the availability of
substantial additional funding for the Company to continue its operations and to conduct research and development,
clinical studies and future product commercialization; and, the Company's business, research, product development,
regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and
described in more detail in our filings with the SEC, including, our current reports on Form 8-K. We do not undertake to
update these forward-looking statements made by us.

For further information, please visit www.delmarpharma.com; or contact Jeffrey A. Bacha, President & CEO (604) 629-
5989 or Gerry Amato, Booke & Company Investor Relations, admin@bookeandco.com
SOURCE DelMar Pharmaceuticals, Inc.